Kobe Steel to Licence Titanium Alloy to Timet

Kobe Steel has entered into an agreement for Titanium Metals Corporation (Timet) to manufacture and market Kobe Steel’s Ti-9 alpha-beta titanium alloy under licence. Under the agreement, Timet will manufacture the alloy in the United States and the UK, as well as marketing it in the US, Mexico, Canada and certain European countries.

The Ti-9 alloy rivals the popular Ti6Al4V titanium alloy for its high strength, but is easier to process and hence is 30% cheaper to manufacture. It has the added advantage that it can be rolled into coils, which Ti6Al4V cannot, which means that it can be produced twice as fast. Ti-9 contains 4.5% aluminium, 2% molybdenum, 1.6% vanadium, 0.5% iron, 0.3% silicon and 0.3% carbon, with the balance being titanium.

Ti-9 is suited to aerospace applications, making it a rival to Ti6Al4V. The aerospace industry consumes some 40% of the 51000 tons of titanium mill products produced in 2001. The new agreement provides Timet with a competitively priced, high performance material for this market.

For more information on titanium and titanium alloys, click here.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kobe Steel. (2019, March 19). Kobe Steel to Licence Titanium Alloy to Timet. AZoM. Retrieved on June 17, 2024 from https://www.azom.com/news.aspx?newsID=183.

  • MLA

    Kobe Steel. "Kobe Steel to Licence Titanium Alloy to Timet". AZoM. 17 June 2024. <https://www.azom.com/news.aspx?newsID=183>.

  • Chicago

    Kobe Steel. "Kobe Steel to Licence Titanium Alloy to Timet". AZoM. https://www.azom.com/news.aspx?newsID=183. (accessed June 17, 2024).

  • Harvard

    Kobe Steel. 2019. Kobe Steel to Licence Titanium Alloy to Timet. AZoM, viewed 17 June 2024, https://www.azom.com/news.aspx?newsID=183.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.